John B. McKune Net Worth

The estimated Net Worth of John Mc Kune is at least $387 mil dollars as of 1 March 2024. Mr Kune owns over 1,078 units of Pulmonx Corp stock worth over $367,428 and over the last few years he sold LUNG stock worth over $19,507.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr McKune LUNG stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Pulmonx Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,078 units of LUNG stock worth $9,767 on 1 March 2024.

The largest trade he's ever made was selling 1,078 units of Pulmonx Corp stock on 1 March 2024 worth over $9,767. On average, Mr trades about 1,010 units every 46 days since 2023. As of 1 March 2024 he still owns at least 47,410 units of Pulmonx Corp stock.

You can see the complete history of Mr Kune stock trades at the bottom of the page.

Mr. John B. McKune biography

John B. McKune is the VP & Controller at Pulmonx Corp.

How old is Mr McKune?

Mr McKune is 45, he's been the VP & Controller of Pulmonx Corp since . There are 5 older and no younger executives at Pulmonx Corp. The oldest executive at Pulmonx Corp is David A. Lehman, 60, who is the Gen. Counsel & Sec..

What's Mr McKune's mailing address?

John's mailing address filed with the SEC is C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Pulmonx Corp

Over the last 4 years, insiders at Pulmonx Corp have traded over $195,808,760 worth of Pulmonx Corp stock and bought 107,681 units worth $1,883,657 . The most active insiders traders include Scientific Corp Boston, Thomas William Burns, eGlendon E. Iii French. On average, Pulmonx Corp executives and independent directors trade stock every 13 days with the average trade being worth of $393,258. The most recent stock trade was executed by Geoffrey Beran Rose on 3 September 2024, trading 4,586 units of LUNG stock currently worth $30,726.

What does Pulmonx Corp do?

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Complete history of Mr Kune stock trades at Pulmonx Corp

Pulmonx Corp executives and stock owners

Pulmonx Corp executives and other stock owners filed with the SEC include:

• Glendon E. French,
  CEO, Pres & Director
• Geoffrey Beran Rose,
  Chief Commercial Officer
• David A. Lehman,
  Gen. Counsel & Sec.
• John B. McKune,
  VP & Controller
• Jérôme Erath,
  Sr. VP & GM of Europe Middle-East & Africa
• Marcee M. Maroney,
  VP of Marketing
• Lauren Cristina,
  VP of Fin. & Admin. (U.S.)
• Sri Radhakrishnan,
  Chief Technical Officer
• Dr. Derrick Sung,
  Chief Financial Officer
• Mehul Joshi,
  Chief Financial Officer & PAO
• Alissa Hsu Lynch,
  Director
• Richard Ferrari,
  
• Staffan Lindstrand,
  Director
• Thomas William Burns,
  
• Dana G Jr. Mead,
  
• Scientific Corp Boston,
  10% owner
• Steven S. Williamson,
  PRESIDENT AND CEO
• Derrick Sung,
  Chief Financial Officer
• Geoffrey Beran Rose,
  CHIEF COMMERCIAL OFFICER
• Glendon E. Iii French,
  
• John Mc Kune,
  INTERIM CFO
• David Aaron Lehman,
  GENERAL COUNSEL
• Daniel P Florin,
  
• Georgia Melenikiotou,
  
• Tiffany Sullivan,